Chinese Journal of Clinical Oncology

, Volume 2, Issue 3, pp 679–684

Anti-tumor effect of CDA-II on a human glioma cell

Authors

  • Hongyan Wang
    • Department of PathologyMedical College of Jinan University
  • Xueyun Zhong
    • Department of PathologyMedical College of Jinan University
  • Frank C. Liu
    • Department of PathologyMedical College of Jinan University
  • Yanfang Qin
    • Department of PathologyMedical College of Jinan University
Original Articles

DOI: 10.1007/BF02739731

Cite this article as:
Wang, H., Zhong, X., Liu, F.C. et al. Chin. J. Clin. Oncol. (2005) 2: 679. doi:10.1007/BF02739731

Abstract

Objective

To examine the effect of uroacitide (CDA-II ), an extraction product from normal human urine, on proliferation and differentiation of human glioma SWO-38 cells.

Methods

The effects of CDA-II on cellular survival and colony formation were determined by MTT and colony-formation assays. The in vivo anti-tumor effect of CDA-II was examined on transplanted SWO-38 cells in nude mice. In addition, the aterations in cell morphology induced by CDA-II were observed by H&E staining.

Results

Treatment of SWO-38 cells with 1–5 mg/ml of CDA-II for 3 days, resulted in 39.49%± 5.27%~65.05%± 5.89% growth inhibition with an IC50of 2.52 mg/ml. Based on the colony-formation assay, 10 days of CDA-II treatment at a level of 0.3~2.1 mg/ml caused 23.45%± 0.62%~96.22%±1.01% inhibition with an IC50 of 1.03 mg/ml. Furthermore, the inhibitory response was dose-dependent. CDA-II at dosage of 500 mg/kg or 2,000 mg/kg per day for 4 weeks significantly suppressed the growth of human glioma SWO-38 cells in nude mice, with inhibition being 47.77% and 79.94%, respectively (P< 0.05, n=10). H&E staining and light microscopy revealed that CDA-II induced differentiation of the SWO-38 cells.

Conclusion

CDA-II has a significant anti-tumor effect on the human glioma SWO-38 cells, and is a potential and natural anti-glioma therapeutic reagent.

Keywords

CDA-IIgliomaanti-tumor effectproliferationinduced differentiation

Copyright information

© Chinese Anti-Cancer Association and Springer 2003